Cigna's announcement on October 30, 2025, of a new rebate-free pharmacy benefit model is a strategic move by Evernorth, designed to enhance transparency and potentially lower costs for clients. This shift is likely to have a multifaceted impact on Evernorth's future revenue streams, particularly within its Pharmacy Benefit Services (PBS) segment.
Evernorth's Pharmacy Benefit Services, which includes functions like drug claim adjudication, formulary management, and home delivery pharmacy, has historically been a significant revenue driver for Cigna. The third quarter 2025 results showed robust adjusted revenue growth of 18% for Pharmacy Benefit Services, reflecting strong organic growth and new business, reaching $34,091 million.1 However, adjusted income from operations for this segment decreased by 6% in the same period, attributed to "strategic investments and initiatives to support business growth."1 It is plausible that the development and implementation of this new rebate-free model contributed to these investments.
The transition to a rebate-free model aims to address growing demands for transparency in the pharmacy benefit management industry. By removing traditional rebates, Evernorth seeks to offer a more straightforward pricing structure, which could attract new clients and strengthen existing relationships. While this model could initially impact revenue components previously tied to rebates, the stated goals of "lower costs, improve transparency, and support local pharmacies" suggest a strategic play for market share and long-term client retention.1 The company's reaffirmation of its 2025 adjusted EPS outlook alongside this announcement indicates management's confidence in navigating this transition and its potential for future growth.1 Ultimately, the success of this model will depend on its ability to deliver on cost savings and transparency for clients, thereby driving sustained volume and revenue growth for Evernorth's PBS segment.
